DTx: A Comeback?

Digital therapeutics (DTx) has been a rapidly growing sector in healthcare, attracting significant investment. However, recent challenges, including market conditions and financing difficulties, have cast a shadow over the industry. 

Many DTx companies are facing cash shortages and are unable to allocate funds for essential activities like clinical research and commercialisation. Additionally, the lack of a clear reimbursement frameworks in many parts of the world has hindered the adoption of DTx products, despite their potential to improve healthcare outcomes. 

In order to succeed, DTx companies need to focus on the economic viability of their products and work towards establishing reimbursement pathways. Industry collaboration, policy changes, and education are necessary to ensure that these innovative solutions can benefit patients and the healthcare system as a whole.

Join this meeting to collaboratively shape the next phase of DTx: